Epstein-Barr virus antibody test is a blood test to detect antibodies to the Epstein-Barr virus (EBV), which is a cause of the infection mononucleosis.
A blood sample is needed.
The sample is sent to a lab, where a lab specialist looks for antibodies to the Epstein-Barr virus. In the first stages of an illness, little antibody may be detected. For this reason, the test is often repeated in 10 days to 2 or more weeks.
There is no special preparation for the test.
When the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.
The test is done to detect an infection with the Epstein-Barr virus (EBV). EBV causes mononucleosis or mono. The EBV antibody test detects not only a recent infection, but also one that occurred in the past. It can be used to tell the difference between a recent or previous infection.
Another test for mononucleosis is called the spot test. It is done when a person has current symptoms of mononucleosis.
A normal result means no antibodies to EBV were seen in your blood sample. This result means you have never been infected with EBV.
Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or test different samples. Talk to your health care provider about the meaning of your specific test results.
A positive result means there are antibodies to EBV in your blood. This indicates a current or prior infection with EBV.
There is very little risk involved with having your blood taken. Veins and arteries vary in size from one person to another and from one side of the body to the other. Taking blood from some people may be more difficult than from others.
Other risks associated with having blood drawn are slight, but may include:
Reviewed By: Jatin M. Vyas, MD, PhD, Assistant Professor in Medicine, Harvard Medical School; Assistant in Medicine, Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.